Investor Alert
Vascepa® (icosapent ethyl) cardiovascular outcomes study, REDUCE-IT™, results are available.
See press release here

DISCOVER

Vascepa®

EXPERIENCED

in lipid science

INVESTOR

relations

Vascepa®

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. For more information about Vascepa visit www.vascepa.com.

Vascepa


The History of Vascepa

Development of Vascepa leveraged Amarin’s extensive experience in lipid sciences and the potential therapeutic benefits of polyunsaturated fatty acids. Such development challenged previously established norms to create a potent, yet safe, targeted single ingredient product in contrast to prior generation omega-3 mixtures and other prescription drugs. The use of Vascepa is now supported by over 40 granted patents and by FDA designation in 2015 of Vascepa’s active ingredient as a New Chemical Entity. This means that no prior FDA-approved drug had the active ingredient contained in Vascepa. Also, no prior drug with icosapent ethyl was ever characterized for FDA review and approved by the FDA to treat or prevent a medical condition.

MORE

recent news


28 Nov 2018

Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference MORE

26 Nov 2018

Amarin Prices Public Offering of American Depositary Shares MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
$16.57
Change:
-0.11
Date:
4:00 PM EDT on Dec 11, 2018
(latest end of day stock price)
Investor
Relations
Executive
Team
Career
Opportunities
FAQs
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe